Keeping Current

• How Are Oral SERDs Changing the Management of Advanced HR-Positive Breast Cancer?

  Where do oral selective estrogen receptor degraders (SERDs) fit in the overall landscape of first- and second-line advanced/metastatic breast cancer? Credit available for this activity expires: 12/04/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/how-are-oral-serds-changing-management-advanced-hr-positive-2025a1000xkg?ecd=bdc_podcast_libsyn_mscpedu

  --------  

  19:55

  --------

  19:55
• Staying Ahead of the First Event: Evaluating the Evidence for Early LDL-C Lowering

  Preventing the first ASCVD is critically important. In this activity, we explore the evidence for early and intensive lipid lowering to significantly reduce patient's cardiovascular (CV) risk. Credit available for this activity expires: 12/05/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/staying-ahead-first-event-evaluating-evidence-early-ldl-c-2025a1000xkj?ecd=bdc_podcast_libsyn_mscpedu

  --------  

  30:36

  --------

  30:36
• Optimizing Outcomes for Patients With IgAN: Novel B-Cell Targeted Therapies and the Changing Treatment Paradigm

  Is your patient's proteinuria low enough? New KDIGO goals: target the immune cause and hit   Credit available for this activity expires: 12/2/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003055?ecd=bdc_podcast_libsyn_mscpedu

  --------  

  32:18

  --------

  32:18
• Advances in the Pharmacologic Management of Obesity: An Expert Digest of the Latest Data

  Are you up to date on emerging pharmacologic therapies transforming obesity and type 2 diabetes care? Credit available for this activity expires: 11/28/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/advances-pharmacologic-management-obesity-expert-digest-2025a1000v94

  --------  

  16:01

  --------

  16:01
• Breaking the Silence: Tackling Liver Fibrosis in MASH: Who to Treat With Novel Therapies

  Do you know whom to treat and why? Learn about identifying and treating at-risk metabolic dysfunction-associated steatohepatitis (MASH). Credit available for this activity expires: 11/25/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/breaking-silence-tackling-liver-fibrosis-mash-who-treat-2025a1000waj?ecd=bdc_podcast_libsyn_mscpedu

  --------  

  18:45

  --------

  18:45

Altri podcast di Salute e benessere

Podcast di tendenza in Salute e benessere

Su Keeping Current